Abstract:Histone deacetylases, as a new class of anticancer targets, could maintain homeostasis by catalyzing histone deacetylation and play important roles in regulating the expression of target genes. Due to the fact that simultaneous intervention with dual tumor related targets could improve treatment effects, researches on innovative design of dual-target drugs are underway. HDAC is known as a "sensitizer" for the synergistic effects with other anticancer-target drugs because of its flexible structure design. The synergistic effects of HDAC inhibitor and other target inhibitors usually show enhanced inhibitory effects on tumor cells, and also provide new strategies to overcome multidrug resistance . Many research groups have reported that simultaneously inhibiting HDAC and other targets, such as tubulin, EGFR , could enhance the therapeutic effects. The o-aminobenzamide group is often used as a ZBG group in the design of HDAC inhibitors with potent antitumor effects . Given the prolonged inhibitory effects and reduced toxic side effects of HDAC inhibitors using o-aminobenzamide as the ZBG group, the o-aminobenzamide group is expected to become a more promising alternative to hydroxamic acid. In fact, o-aminobenzamide-based dual inhibitors of HDAC with different chemical structures have been extensively prepared and reported with synergistic and enhanced anti-tumor effects. In this work, we first time reviewed the rational design, molecular docking, inhibitory activities and potential application of o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities in cancer therapy, which might provide a reference for developing new and more effective anticancer drugs.

Tubulin/HDAC dual-target inhibitors: Insights from design strategies, SARs, and therapeutic potential

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

HDAC-targeting epigenetic modulators for cancer immunotherapy

Discovery of Chiral 1,4-Diarylazetidin-2-one-Based Hydroxamic Acid Derivatives as Novel Tubulin Polymerization Inhibitors with Histone Deacetylase Inhibitory Activity

A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy

Development of a novel class of tubulin inhibitors with promising anticancer activities.

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization

Design, Synthesis and Anticancer Evaluation of Acridine Hydroxamic Acid Derivatives As Dual Topo and HDAC Inhibitors.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton

Advances in targeting histone deacetylase for treatment of solid tumors

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Computational Approaches to the Rational Design of Tubulin-Targeting Agents

Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Design, Synthesis, Antitumor Activities and Biological Studies of Novel Diaryl Substituted Fused Heterocycles As Dual Ligands Targeting Tubulin and Katanin.